Alpelisib
Spezifikationen
1217486-61-7CAS-Nummer
806-598-7EG-Nummer
(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamideIUPAC-Name
C19H22F3N5O2SChemische Formel
441.5 g/molMolekulargewicht
alpelisib; 1217486-61-7; BYL-719; BYL719; Piqray; NVP-BYL719; Vijoice; BYL 719; 08W5N2C97Q; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; 1,2-Pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2S)-; 1,2-PYRROLIDINEDICARBOXAMIDE, N1-[4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL]-2-THIAZOLYL]-, (2S)-; DTXSID70153355; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide; alpelisibum; (2S)-1-N-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)-1,3-thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; (2S)-1-N-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide; (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl]thiazol-2-yl]amide; RefChem:57062; DTXCID7075846; L01XX65; Phosphoinositide 3-kinase Inhibitor BYL719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; UNII-08W5N2C97Q; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; Alpelisib [USAN:INN]; MFCD22417085; CHEMBL2396661; (2s)-N~1~-{4-Methyl-5-[2-(1,1,1-Trifluoro-2-Methylpropan-2-Yl)pyridin-4-Yl]-1,3-Thiazol-2-Yl}pyrrolidine-1,2-Dicarboxamide; (S)-N1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.; Alpelisib [INN]; C19H22F3N5O2S; A lpelisib; 4jps; 1LT; Alpelisib [USAN]; Vijoice (TN); Piqray (TN); ALPELISIB [JAN]; ALPELISIB [MI]; ALPELISIB [WHO-DD]; Alpelisib (JAN/USAN/INN); GTPL7955; orb1226776; orb1307105; SCHEMBL1911869; ALPELISIB [ORANGE BOOK]; SCHEMBL29358059; CHEBI:93752; EX-A405; STUWGJZDJHPWGZ-LBPRGKRZSA-N; BDBM738244; BYL 719; BYL719; GLXC-90284; BDBM50436459; EBC-11472; NSC765974; NSC800065; s2814; AKOS022186315; CCG-269139; CS-0663; DB12015; FP71607; NSC-765974; NSC-800065; SDCCGSBI-0654479.P001; US20250145589, Example Alpelisib; NCGC00346717-03; NCGC00346717-06; NCGC00346717-09; NCGC00346717-12; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine; (2S)-N1-{4-METHYL-5-[2-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL]-1,3-THIAZOL-2-YL}PYRROLIDINE-1,2-DICARBOXAMIDE; AC-37083; AS-16349; HY-15244; B9700; NS00072895; SW220128-1; cas:1217486-61-7;BYL-719; D11011; EN300-23810842; BRD-K54997624-001-06-0; Q27074391; (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-4-pyridyl]thiazol-2-yl]pyrrolidine-1,2-dicarboxamide; (2S)-N1-{4-Methyl-5-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide; BYL-719A-1214(S)-N1-(4-METHYL-5-(2-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL)THIAZOL-2-YL)PYRROLIDINE-1,2-DICARBOXAMIDESynonyme
Produkte, die Alpelisib enthalten
피크레이정50밀리그램(알펠리십), 피크레이정150밀리그램(알펠리십), 피크레이정200밀리그램(알펠리십)PIQRAY 50 MG y 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPIQRAY 50 mg et 200 mg, comprimé pelliculéPIQRAY 200 mg, comprimé pelliculéPIQRAY 150 mg, comprimé pelliculéAlpelisib - Novartis Pharmaceuticals CorporationAlpelisib - ArevipharmaAlpelisibAlpelisibAlpelisib
